<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article117</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/DINAMIT" style="display:block; margin-bottom:10px;">DINAMIT Original</a></li>
<h2><strong>DINAMIT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo". The New England Journal of Medicine. 1991. 324(12):781-788.<br/>
<br/>
## Clinical Question<br/>
Does implantable cardioverter-defibrillator (ICD) therapy improve survival among patients early after myocardial infarction with reduced left ventricular function and impaired cardiac autonomic function?<br/>
<br/>
## Bottom Line<br/>
Prophylactic ICD therapy does not reduce overall mortality among high-risk patients who have recently had a myocardial infarction. Although ICD therapy was associated with a reduction in the rate of death due to arrhythmia, this benefit was offset by an increase in the rate of death from nonarrhythmic causes.<br/>
<br/>
## Major Points<br/><br/>
<br/>
## Guidelines<br/>
Current guidelines do not recommend routine prophylactic ICD implantation early after myocardial infarction.<br/>
<br/>
## Design<br/>
- Multicenter, randomized, open-label trial<br/>
- N=674 patients with a recent MI (6 to 40 days previously)<br/>
- Intervention: ICD therapy (n=332)<br/>
- Control: No ICD therapy (n=342)<br/>
- Mean follow-up: 30±13 months<br/>
- Primary outcome: Mortality from any cause<br/>
- Secondary outcome: Death from arrhythmia<br/>
<br/>
## Population<br/>
### Inclusion Criteria<br/>
- Age 18 to 80 years<br/>
- Recent MI (6 to 40 days prior)<br/>
- Left ventricular ejection fraction ≤0.35<br/>
- Impaired cardiac autonomic function (SDNN ≤70 ms or mean RR interval ≤750 ms over 24 hours)<br/>
<br/>
### Exclusion Criteria<br/>
- Congestive heart failure or NYHA class IV at randomization<br/>
- Expected pacemaker requirement<br/>
<br/>
### Baseline Characteristics<br/>
- Age: 61.7 years<br/>
- Male: 74.7%<br/>
- Mean left ventricular ejection fraction: 0.28<br/>
<br/>
## Interventions<br/>
- ICD implantation within one week after randomization in the ICD group<br/>
- Optimal medical therapy for all patients<br/>
<br/>
## Outcomes<br/>
### Primary Outcome<br/>
- No significant difference in overall mortality between groups (ICD 7.5% vs Control 6.9% annual mortality rates)<br/>
### Secondary Outcomes<br/>
- Decreased deaths from arrhythmia in the ICD group (ICD 1.5% vs Control 3.5% annual rates)<br/>
- Increased nonarrhythmic deaths in the ICD group (ICD 7.6% vs Control 4.4% annual rates)<br/>
<br/>
## Criticisms<br/>
- The reason for the increased nonarrhythmic deaths in the ICD group is unclear<br/>
- The trial did not support an ICD benefit in this patient population despite previous studies suggesting a potential survival advantage<br/>
<br/>
## Funding<br/>
Supported by St. Jude Medical, grant holder.<br/>
<br/>
## Further Reading<br/>
- Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-2488.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
